Supplementary Table S1 from Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes

Supplementary Table S1 - PDF file 69K, Summary of macroscopic CNAs and LOH alterations identified in MDS patients and response to fourth cycle of 5d-Aza. The table summarizes the results of SNP karyotyping, LOH and CNAs in the 26 MDS patients for whom the an